Yiqi Fumai Lyophilized Injection ameliorates heart failure induced by transverse aortic constriction via Piezo1/NO/cGMP pathway
DAI Sufang, ZHAO Qingfei, LIU Jincheng, HUANG Zixuan, XU Jinta, LI Fang, KOU Junping
Affiliations
1 Jiangsu Provincial Key Laboratory of Traditional Chinese Medicine Evaluation and Transformation, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China
doi: 10.7501j.issn.0253-2670.2026.19.015
文章导航
摘要
收起
目的 探讨注射用益气复脉（冻干）（Yiqi Fumai Lyophilized Injection，YQFM）通过上调心脏内皮机械敏感离子通道（piezo-type mechanosensitive ion channel component 1，Piezo1）激活一氧化氮（nitric oxide，NO）信号通路，从而抑制心肌肥大，改善压力超负荷所致心力衰竭（heart failure，HF）。方法 采用主动脉弓缩窄（transverse aortic constriction，TAC）手术制备小鼠HF模型，术后2周ip不同剂量YQFM（0.13、0.26、0.53 g/kg）和卡托普利（20 mg/kg）进行干预。药物干预4周后利用超声心动图评估心功能变化；采用苏木素-伊红（hematoxylin-eosin，HE）和Masson染色评价心脏病理损伤及纤维化程度；采用心脏指数、心脏质量与胫骨长度比值、小麦胚芽凝集素（wheat germ agglutinin，WGA）染色评价心脏重构和心肌细胞肥大程度；采用血清生化检测、qRT-PCR、Western blotting及免疫荧光染色等技术检测HF相关标志物及Piezo1/NO通路关键蛋白的表达变化。结果 YQFM显著改善TAC诱导的小鼠心功能障碍与心脏重构（P＜0.05、0.01），并减轻组织结构紊乱、心肌细胞肥大和心肌纤维化（P＜0.01）。机制研究表明YQFM降低血清心肌损伤标志物心肌肌钙蛋白T（cardiac troponin T，cTn-T）、N末端B型利钠肽前体（N-terminal pro-B-type natriuretic peptide，NT-proBNP）水平（P＜0.01），显著下调心脏中肥大相关基因心房钠尿肽（natriuretic peptide A，Nppa）、B型利钠肽（natriuretic peptide B，Nppb）、肌球蛋白重链7（myosin heavy chain 7，Myh7）与纤维化相关基因I型胶原蛋白α1链（collagen type I alpha 1 chain，Col1a1）、Ⅲ型胶原蛋白α1链（collagen type III alpha 1 chain，Col3a1）的表达（P＜0.05、0.01）。YQFM还可显著降低卵泡抑素样蛋白1（follistatin-like 1，Fstl1）和内皮素-1（endothelin-1，ET-1）含量（P＜0.05、0.01），同时提升血清与心脏组织中NO及环磷酸鸟苷（cyclic guanosine monophosphate，cGMP）水平（P＜0.01）。此外，YQFM显著上调心脏内皮细胞中Piezo1蛋白与磷酸化内皮型一氧化氮合酶（phosphorylated endothelial nitric oxide synthase，p-eNOS）的表达（P＜0.01）。结论 YQFM通过上调内皮Piezo1表达并激活eNOS/NO通路，改善心脏功能与重构，抑制心肌细胞肥大，从而发挥抗HF作用。
Objective To investigate whether Yiqi Fumai Lyophilized Injection [注射用益气复脉（冻干）, YQFM] ameliorates myocardial hypertrophy and pressure overload-induced heart failure (HF) by upregulating the cardiac endothelial mechanosensitive ion channel Piezo1 and activating the nitric oxide (NO) signaling pathway. Methods A mouse HF model was prepared via transverse aortic constriction (TAC) surgery. Two weeks post-operation, mice received intraperitoneal injections of different doses of YQFM (0.13, 0.26, 0.53 g/kg) or captopril (20 mg/kg) for four weeks. Cardiac function was assessed by echocardiography. Pathological injury and fibrosis were evaluated by hematoxylin and eosin (HE) and Masson staining. Cardiac remodeling and cardiomyocyte hypertrophy were assessed by heart index, heart weight-to-tibia length ratio and wheat germ agglutinin (WGA) staining. Serum biochemical assays, qRT-PCR, Western blotting and immunofluorescence were employed to detect HF-related biomarkers and the expressions of key proteins in Piezo1/NO pathway. Results YQFM significantly improved TAC-induced cardiac dysfunction and remodeling (P < 0.05, 0.01), and alleviated histopathological disorganization, cardiomyocyte hypertrophy and myocardial fibrosis (P < 0.01). Mechanistic studies showed that YQFM reduced levels of cardiac injury markers cardiac troponin T (cTn-T) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in serum (P < 0.01), and significantly downregulated the expressions of hypertrophy-related genes natriuretic peptide A (Nppa), natriuretic peptide B (Nppb), myosin heavy chain 7 (Myh7) and fibrosis-related genes collagen type I alpha 1 chain (Col1a1), collagen type III alpha 1 chain (Col3a1) in cardiac tissue (P < 0.05, 0.01). YQFM significantly decreased the levels of follistatin-like 1 (Fstl1) and endothelin-1 (ET-1) (P < 0.05, 0.01), while elevating the levels of NO in serum and cardiac tissue and cyclic guanosine monophosphate (cGMP) in cardiac tissue (P < 0.01). Furthermore, YQFM significantly upregulated the expressions of Piezo1 protein and phosphorylated endothelial nitric oxide synthase (p-eNOS) in cardiac endothelial cells (P < 0.01). Conclusion YQFM improves cardiac function and remodeling, and inhibits cardiomyocyte hypertrophy in HF by upregulating endothelial Piezo1 expression and activating eNOS/NO signaling pathway.
DAI Sufang, ZHAO Qingfei, LIU Jincheng, HUANG Zixuan, XU Jinta, LI Fang, KOU Junping.
Yiqi Fumai Lyophilized Injection ameliorates heart failure induced by transverse aortic constriction via Piezo1/NO/cGMP pathway[J].
Chinese Traditional and Herbal Drugs,
2026
, 57
(19)
: 7685
-7696
.
DOI: 10.7501j.issn.0253-2670.2026.19.015
基金
收起
国家自然科学基金面上项目 (82274140)
参考文献
收起
文献
收起
参考文献引证文献
排序方式：
Oldfield C J, Duhamel T A, Dhalla N S. Mechanisms for the transition from physiological to pathological cardiac hypertrophy [J]. Can J Physiol Pharmacol, 2020, 98(2): 74-84. Fu J, Su C P, Ge Y, et al. PDE4D inhibition ameliorates cardiac hypertrophy and heart failure by activating mitophagy [J]. Redox Biol, 2025, 81: 103563. Liu X J, Li H B, Hastings M H, et al. miR-222 inhibits pathological cardiac hypertrophy and heart failure [J]. Cardiovasc Res, 2024, 120(3): 262-272. Shi S G, Jiang P D. Therapeutic potentials of modulating autophagy in pathological cardiac hypertrophy [J]. Biomed Pharmacother, 2022, 156: 113967. Wu H, Zhuang Y T, Yue Y, et al. SPOP is a key trigger of pathological cardiac hypertrophy and heart failure [J]. Circ Res, 2025, 137(9): e177-e196. Xiao C C, Wang C, Wang J Y, et al. FMO2 prevents pathological cardiac hypertrophy by maintaining the ER-mitochondria association through interaction with IP3R2-Grp75-VDAC1[J]. Circulation, 2025, 151(23): 1667-1685. Zhou H B, Wang X, Xu T Y, et al. PINK1-mediated mitophagy attenuates pathological cardiac hypertrophy by suppressing the mtDNA release-activated cGAS-STING pathway [J]. Cardiovasc Res, 2025, 121(1): 128-142. Wang X, He B. Endothelial dysfunction: Molecular mechanisms and clinical implications [J]. MedComm, 2024, 5(8): e651. 王颖婷, 嘎珍, 张林泉, 等. 内皮型一氧化氮合酶在心血管疾病中的调节作用研究进展[J]. 医学理论与实践, 2023, 36(6): 926-928. Friedrich E E, Hong Z G, Xiong S Q, et al. Endothelial cell Piezo1 mediates pressure-induced lung vascular hyperpermeability via disruption of adherens junctions [J]. Proc Natl Acad Sci USA, 2019, 116(26): 12980-12985. Siragusa M, Oliveira Justo A F, Malacarne P F, et al. VE-PTP inhibition elicits eNOS phosphorylation to blunt endothelial dysfunction and hypertension in diabetes [J]. Cardiovasc Res, 2021, 117(6): 1546-1556. Zhang Y H, Su S G, Li W D, et al. Piezo1-mediated mechanotransduction promotes cardiac hypertrophy by impairing calcium homeostasis to activate calpain/calcineurin signaling [J]. Hypertension, 2021, 78(3): 647-660. 鞠爱春, 罗瑞芝, 秦袖平, 等. 注射用益气复脉(冻干)药理作用及临床研究进展[J]. 药物评价研究, 2018, 41(3): 354-364. 孟骊冲, 王梓仪, 李欣春, 等. 中药注射剂治疗慢性心力衰竭的研究进展[J]. 中草药, 2026, 57(3): 1179-1194. 褚延斌, 苏小琴, 李德坤, 等. 基于一测多评法对注射用益气复脉(冻干)中糖类成分的质量控制研究[J]. 药物评价研究, 2018, 41(3): 451-456. 褚延斌, 苏小琴, 李德坤, 等. 基于一测多评法对注射用益气复脉(冻干)中9种成分的质量控制研究[J]. 中草药, 2017, 48(17): 3537-3544. 张磊, 苏小琴, 陈昊喆, 等. 基于质量标志物的注射用益气复脉(冻干)质量评价与监测技术研究进展[J]. 药物评价研究, 2023, 46(8): 1778-1786. 刘红宇, 徐玉琴, 欧阳婷, 等. 益气复脉冻干粉与其单味药配方液HPLC指纹图谱差异性研究[J]. 中国中医药信息杂志, 2018, 25(8): 70-74. Lv S C, Wang Y J, Zhang W Q, et al. The chemical components, action mechanisms, and clinical evidences of YiQiFuMai Injection in the treatment of heart failure [J]. Front Pharmacol, 2022, 13: 1040235. Zhang Y, Zhang L, Zhang Y, et al. YiQiFuMai Powder Injection attenuates coronary artery ligation-induced heart failure through improving mitochondrial function via regulating ROS generation and CaMKII signaling pathways [J]. Front Pharmacol, 2019, 10: 381. 冯岩, 荣娜, 张银桥. 注射用益气复脉治疗慢性心力衰竭对血管内皮功能的影响分析[J]. 现代医学与健康研究电子杂志, 2025, 9(1): 118-120. Bosch L, de Haan J J, Bastemeijer M, et al. The transverse aortic constriction heart failure animal model: A systematic review and Meta-analysis [J]. Heart Fail Rev, 2021, 26(6): 1515-1524. Li F, Pang L Z, Zhang L, et al. YiQiFuMai Powder Injection ameliorates chronic heart failure through cross-talk between adipose tissue and cardiomyocytes via up-regulation of circulating adipokine omentin [J]. Biomed Pharmacother, 2019, 119: 109418. 周超雄. 核因子-κB活化对重症急性胰腺炎大鼠心肌损害的实验研究[D]. 青海: 青海大学, 2011. Baman J R, Ahmad F S. Heart failure [J]. Jama, 2020, 324(10): 1015. 曾文如, 王东伟, 邵晓奇. 小鼠横向主动脉弓缩窄与异丙肾上腺素注射构建心肌肥厚模型方法的比较[J]. 广东药科大学学报, 2023, 39(1): 122-128. 俞鹏, 沈乐, 史海波, 等. 注射用益气复脉(冻干)临床应用中国专家共识[J]. 药物评价研究, 2025, 48(9): 2389-2400. 石瑛, 牟鑫, 丁伟. 益气复脉注射液治疗气阴两虚证心衰效果观察[J]. 中国城乡企业卫生, 2026, 41(1): 193-195. 谷阳, 刘红阳, 姚毅仁, 等. 注射用益气复脉治疗早发心肌梗死的效果[J]. 辽宁中医杂志, 2026: 1-6. 杜浩, 戚先伟, 陶军, 等. 注射用益气复脉（冻干）联合替罗非班治疗急性心肌梗死的临床研究[J]. 现代药物与临床, 2025, 40(6): 1445-1450. Pang L Z, Ju A C, Zheng X J, et al. YiQiFuMai Powder Injection attenuates coronary artery ligation-induced myocardial remodeling and heart failure through modulating MAPKs signaling pathway [J]. J Ethnopharmacol, 2017, 202: 67-77. Wan M X, Yin K K, Yuan J, et al. YQFM alleviated cardiac hypertrophy by apoptosis inhibition and autophagy regulation via PI3K/Akt/mTOR pathway [J]. J Ethnopharmacol, 2022, 285: 114835. 杨莎莎, 柳甜, 王辉波. cGAS-STING信号通路在心肌重构中的调控作用[J]. 中国心血管杂志, 2025, 30(5): 625-630. Adao D M T, Ching C, Fish J E, et al. Endothelial cell-cardiomyocyte cross-talk: Understanding bidirectional paracrine signaling in cardiovascular homeostasis and disease [J]. Clin Sci, 2024, 138(21): 1395-1419. Ding M G, Shi R, Du Y Y, et al. O-GlcNAcylation-mediated endothelial metabolic memory contributes to cardiac damage via small extracellular vesicles [J]. Cell Metab, 2025, 37(6): 1344-1363. Luo M, Lin H C, Wen Z Q, et al. Sodium ferulate inhibits rat cardiomyocyte hypertrophy induced by angiotensin II through enhancement of endothelial nitric oxide synthase/nitric oxide/cyclic guanosine monophosphate signaling pathway [J]. J Cardiovasc Pharmacol, 2022, 80(2): 251-260. Fukuma N, Tokiwa H, Numata G, et al. Endothelial oestrogen-myocardial cyclic guanosine monophosphate axis critically determines angiogenesis and cardiac performance during pressure overload [J]. Cardiovasc Res, 2024, 120(15): 1884-1897. Eley L, Richardson R V, Alqahtani A, et al. eNOS plays essential roles in the developing heart and aorta linked to disruption of Notch signalling [J]. Dis Model Mech, 2024, 17(1): dmm050265. Lee D I, Zhu G S, Sasaki T, et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease [J]. Nature, 2015, 519(7544): 472-476. Chen L Q, Zhou X H, Deng Y J, et al. Zhenwu Decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase)-cGMP (cyclic guanosine monophosphate)-PKG (protein kinase G) pathway [J]. J Ethnopharmacol, 2023, 300: 115705. Bartoli F, Debant M, Chuntharpursat-Bon E, et al. Endothelial Piezo1 sustains muscle capillary density and contributes to physical activity [J]. J Clin Invest, 2022, 132(5): e141775. Meng L L, Lu Y, Wang X L, et al. NPRC deletion attenuates cardiac fibrosis in diabetic mice by activating PKA/PKG and inhibiting TGF-β1/Smad pathways [J]. Sci Adv, 2023, 9(31): eadd4222. Gong S S, Chen H, Fang S H, et al. Ginsenoside Rh1 mitigates mitochondrial dysfunction induced by myocardial ischaemia through its novel role as a sirtuin 3 activator [J]. Br J Pharmacol, 2025, 182(13): 3017-3035. Zhang R, Lu M L, Ran C Y, et al. Ginsenoside Rg1 improves hypoxia-induced pulmonary vascular endothelial dysfunction through TXNIP/NLRP3 pathway-modulated mitophagy [J]. J Ginseng Res, 2025, 49(1): 80-91. Wang Z C, Niu K M, Wu Y J, et al. A dual Keap1 and p47(phox) inhibitor ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis [J]. Cell Death Dis, 2022, 13(9): 824. 赵玲琳, 张勇, 薛慧, 等. 麦冬皂苷D对大鼠心肌细胞缺氧复氧损伤的保护作用及机制研究[J]. 中国循环杂志, 2022, 37(2): 178-184. 赵志成, 梁国英. 麦冬皂苷D调节SphK1/S1P/S1PR1信号通路对心肌缺血再灌注损伤大鼠心肌炎症的影响[J]. 中药新药与临床药理, 2024, 35(11): 1698-1704. 聂彤. 麦冬皂苷D调控TAC诱导心力衰竭能量代谢的作用机制研究[D]. 天津: 天津中医药大学, 2023. Fang D Z, Shang Q X, Liu Z H, et al. Exploring the protective effects of schisandrin A and schisandrin B against diabetic cardiomyopathy with a possible mechanism involving complement inhibition [J]. Phytother Res, 2025, 39(12): 5506-5520. Niu Z C, Jin Q, Shen Q Y, et al. Schisandrol B alleviated diabetic cardiac injury by inhibiting ferroptosis and improving lipid metabolism in mice [J]. Phytomedicine, 2025, 143: 156902.
PDF下载
全屏
37
8
关闭全屏
北京市海淀区学院南路86号
010-62662699（运营及技术支持）
qkjq@cast.org.cn
